Sage Therapeutics Croissance future

Future contrôle des critères 2/6

Sage Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 36% et de 31.9% par an respectivement. Le BPA devrait croître de de 36.6% par an. Le rendement des capitaux propres devrait être -117.4% dans 3 ans.

Informations clés

36.0%

Taux de croissance des bénéfices

36.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	31.9%
Rendement futur des capitaux propres	-117.4%
Couverture par les analystes	Good
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:SAGE - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	158	-200	-85	-123	17
12/31/2025	96	-250	-264	-231	19
12/31/2024	42	-401	-327	-272	19
9/30/2024	106	-338	-320	-320	N/A
6/30/2024	97	-446	-374	-374	N/A
3/31/2024	91	-503	-425	-425	N/A
12/31/2023	86	-541	-541	-541	N/A
9/30/2023	11	-656	-549	-548	N/A
6/30/2023	10	-592	-532	-531	N/A
3/31/2023	9	-558	-507	-506	N/A
12/31/2022	8	-533	-461	-460	N/A
9/30/2022	6	-510	-432	-431	N/A
6/30/2022	6	-503	-381	-381	N/A
3/31/2022	6	-484	-377	-377	N/A
12/31/2021	6	-458	-379	-378	N/A
9/30/2021	1,114	642	730	730	N/A
6/30/2021	1,114	666	708	708	N/A
3/31/2021	1,113	637	692	692	N/A
12/31/2020	1,114	606	664	664	N/A
9/30/2020	7	-537	-464	-463	N/A
6/30/2020	9	-612	-504	-501	N/A
3/31/2020	9	-644	-520	-515	N/A
12/31/2019	7	-680	-534	-529	N/A
9/30/2019	5	-670	-520	-514	N/A
6/30/2019	2	-613	-470	-465	N/A
3/31/2019	91	-462	-335	-332	N/A
12/31/2018	90	-373	-264	-261	N/A
9/30/2018	90	-284	-221	-218	N/A
6/30/2018	90	-235	N/A	-184	N/A
3/31/2018	N/A	-288	N/A	-243	N/A
12/31/2017	N/A	-270	N/A	-219	N/A
9/30/2017	N/A	-257	N/A	-194	N/A
6/30/2017	N/A	-221	N/A	-179	N/A
3/31/2017	N/A	-185	N/A	-146	N/A
12/31/2016	N/A	-159	N/A	-119	N/A
9/30/2016	N/A	-132	N/A	-103	N/A
6/30/2016	N/A	-118	N/A	-92	N/A
3/31/2016	N/A	-108	N/A	-84	N/A
12/31/2015	N/A	-94	N/A	-71	N/A
9/30/2015	N/A	-78	N/A	-61	N/A
6/30/2015	N/A	-64	N/A	-49	N/A
3/31/2015	N/A	-47	N/A	-36	N/A
12/31/2014	N/A	-36	N/A	-27	N/A
9/30/2014	N/A	-29	N/A	-23	N/A
6/30/2014	N/A	-24	N/A	-21	N/A
3/31/2014	N/A	-21	N/A	-20	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SAGE devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: SAGE devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: SAGE devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SAGE ( 31.9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SAGE ( 31.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: SAGE devrait être non rentable dans 3 ans.

Sage Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 32%, EPS downgraded

Price target decreased by 13% to US$24.39

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Price target decreased by 13% to US$21.94

Consensus revenue estimates fall by 57%

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

CNS Drug Development: Same As It Ever Was

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%